Effect of Xindili Monoclonal Antibody Injection Combined with XELOX Regimen on PD-1,PD-L1 Expression and Peripheral Blood Myeloid-Derived Suppressor Cells and Regulatory T Cells in Patients with Advanced Gastric Cancer
Objective:To observe the effect of xindili monoclonal antibody injection combined with oxaliplatin and capecitabine(XELOX)regimen on the expression of programmed death receptor-1(PD-1)and programmed death ligand-1(PD-L1)and peripheral blood myeloid-derived suppressor cells(MDSCs)and regulatory T cells(Treg)in patients with advanced gastric cancer.Methods:121 patients with advanced gastric cancer received in our hospital from April 2021 to March 2023 were selected.Patients were divided into control group(n=60,received XELOX regimen)and observation group(n=61,received xindili monoclonal antibody injection combined with XELOX regimen)according to the random number table method.The efficacy,incidence of adverse reactions,tumor markers,rela-tive expression of PD-1 and PD-L1 mRNA,and the ratio of Treg and MDSCs to peripheral blood mononuclear cells(PBMC)were com-pared between two groups.Results:Compared with the ORR(25.00％)and DCR(48.33％)in control group,the ORR(40.98％)and DCR(73.77％)in observation group were higher(P＜0.05).After treatment,the relative expression of carbohydrate antigen 125(CA125),carcinoembryonic antigen(CEA),squamous cell carcinoma antigen(SCC-Ag),PD-1,PD-L1 mRNA,the ratio of Treg and MDSCs to PBMC in observation group were lower than those in control group(P＜0.05).There was no difference in the incidence of adverse reac-tions between two groups(P＞0.05).Conclusion:Xindili monoclonal antibody injection combined with XELOX regimen in the treatment of patients with advanced gastric cancer,which can reduce the level of serum tumor markers,regulate the expression of PD-1,PD-L1 and the ratio of Treg and MDSCs to PBMC,and effectively control the progression of the disease.
NETL
NSTL
万方数据
